News

Despite Revenue Jump, Novavax Appears Immune To Long-Term Growth
Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...
Moderna: Ready For The Redemption Arc
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
Zacks Investment Research on MSN1h
Molina to Report Q2 Earnings: Healthy Revenues, Weak Pulse on Earnings
Healthcare plan provider, Molina Healthcare, Inc. MOH, is set to report second-quarter 2025 results on July 23, 2025, after ...
Novartis1d
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...
Zacks Investment Research on MSN4h
Thermo Fisher (TMO) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Analysts on Wall Street project that Thermo Fisher Scientific (TMO) will announce quarterly earnings of $5.22 per share in its forthcoming report, representing a decline of 2.8% year over year.
IBM and Moderna Team Up on Quantum Study. What It Means for the World of Medicine.
International Business Machines said Thursday that it had joined forces with Moderna for a case study that evidenced quantum ...